WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 28-May-2015 (Data received as of 22-May-2015)
Next overall update July 2015
2014 data are provisional
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 3'7501 Infant (under 12 months) mortality rate: 292
GDP / capita (US$): 6'5511 Child (under 5 years) mortality rate: 352

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 804  800  795  791  786  744  725  777 
Births 16  16  16  17  17  16  17  23 
Surviving infants 16  16  16  16  16  16  16  21 
Pop. less than 5 years 80  84  89  93  98  87  85  119 
Pop. less than 15 years 284  289  292  294  295  263  250  330 
Female 15-49 years 205  203  202  201  200  193  198  185 

Number of reported case

(Click for retrospective incidence data for Guyana)
Diphtheria
Japanese encephalitis
Measles 464 
Mumps
Pertussis 61 
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal) 1'010 
Tetanus (total)** 1'010  20 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Guyana)
Vaccine year result method % card seen                                                
BCG 2007  94  DHS   88  99  98  98  97  98  93  85  68 
DTP1 2007  92  DHS   88  99*  98  99  92  99*  97 
DTP3 2007  85  DHS   88  99*  98  97  93  95  88  82  36 
HepB_BD         
HepB3 2007  85  DHS   88  98  98  97  93  95 
Hib3 2007  85  DHS   88  98  98  97  93  95 
JapEnc         
MCV          99*  99*  99  98  95  86  73 
MCV2          91  95  90  84  82 
PCV1          98  98  94  78 
PCV3          97  96  90  50 
Pol3 2007  70  DHS   88  97  98  97  93  95  79  79  42 
Rota1          99  97  95  82  70 
Rota_last          95  94  91  77  38 
Rubella1          99*  99*  99  98  95 
TT2plus 1999  61  MICS   89  99  99  95  97  97  81 
PAB         
VAD1         
YFV 2007  79  DHS   88  99*  99*  99  97  95  83 
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Guyana)
BCG 98  98  97  98  93  85  68 
DTP1 98  99  97  99  97  94  60 
DTP3 98  97  93  95  88  83  35 
HepB3 98  97  93  95 
HepB_BD
Hib3 98  97  93  95 
MCV 99  99  98  95  86  73 
MCV2 95  90  84  82 
PAB 90  90  90  97  82  56 
PCV3 96  90  50 
Pol3 98  97  93  95  79  79  42 
Rota_last 94  91  77  39 
YFV 99  99  97  94  83 

Number of districts in the country 13  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 77
From 80 to 89% 23
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 2 months; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HIB 2, 4, 6 months; Yes
HPV 1st contact; +1, +6 months; special groups
HepB_Adult +1, +5 months; Yes
IPV 2, 4, 6, 18 months; 3 years; No special groups
MMR 12 months; 3 years and 9 months; Yes
MenACW No special groups
OPV 2, 4, 6, 18 months; 3 years; Yes
Pneumo_conj 2, 4, 6 months; Yes
Pneumo_ps No special groups
Rotavirus 2, 4, 6 months; Yes
Td 15 years; Yes adults and pregnant women
YF 12 months; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2013-2018  2006-2015  2006-2015  2006-2015  2008-2015  2007-2012  2007-2012 
Nº of districts with microplans that include activities to raise immunization coverage number 13  13  13  13  13  13  13 

System performance

Total Nº districts in country number 13  13  13  13  13  13  13 
Nº districts with DTP3 coverage >=80% number 13  13  12  12  13  13 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  92  92  100  100 
Nº districts with measles (MCV1) coverage >=95% number  
% of districts with MCV1 coverage >=95% From 0 to 100% 54  62  69  62    62  62 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  No  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 91  79  71  56  67  88  89 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  No     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.